BIO-key International Faces Delisting Concerns
Ticker: BKYI · Form: 8-K · Filed: Nov 7, 2025 · CIK: 1019034
Sentiment: bearish
Topics: delisting, listing-standards
TL;DR
BIO-key might get delisted, stock could tank.
AI Summary
BIO-key International, Inc. filed an 8-K on November 7, 2025, reporting a notice of delisting or failure to meet continued listing standards. The company, incorporated in Delaware, is based in Holmdel, NJ, and its principal executive offices are located at 101 Crawfords Corner Road, Suite 4116. The filing date for this report is November 7, 2025, with the earliest event reported on November 6, 2025.
Why It Matters
This filing indicates potential issues with BIO-key International's ability to remain listed on its current exchange, which could significantly impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued operation as a publicly traded entity.
Key Players & Entities
- BIO-key International, Inc. (company) — Registrant
- November 6, 2025 (date) — Earliest event reported
- November 7, 2025 (date) — Filing date
- 101 Crawfords Corner Road Suite 4116 Holmdel, NJ 07733 (address) — Principal executive offices
FAQ
What specific listing rule or standard has BIO-key International failed to meet?
The filing does not specify the exact rule or standard that BIO-key International has failed to meet, only that it is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard'.
What is the earliest date of the event reported in this 8-K?
The earliest event reported in this 8-K is November 6, 2025.
When was this Form 8-K filed with the SEC?
This Form 8-K was filed with the SEC on November 7, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 101 Crawfords Corner Road, Suite 4116, Holmdel, NJ 07733.
What is the Commission File Number for BIO-key International, Inc.?
The Commission File Number for BIO-key International, Inc. is 001-13463.
Filing Stats: 697 words · 3 min read · ~2 pages · Grade level 12.2 · Accepted 2025-11-07 16:45:12
Key Financial Figures
- $1.00 — ment to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listi
- $1 — the Company's common stock is at least $1 per share for a minimum of 10 consecuti
Filing Documents
- bkyi20251107_8k.htm (8-K) — 24KB
- 0001437749-25-033877.txt ( ) — 155KB
- bkyi-20251106.xsd (EX-101.SCH) — 3KB
- bkyi-20251106_def.xml (EX-101.DEF) — 12KB
- bkyi-20251106_lab.xml (EX-101.LAB) — 15KB
- bkyi-20251106_pre.xml (EX-101.PRE) — 12KB
- bkyi20251107_8k_htm.xml (XML) — 3KB
01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on May 9, 2025, BIO-key International, Inc. (the " Company ") received notice from the staff of The Nasdaq Stock Market, LLC (" Nasdaq ") stating that the Company did not satisfy the continued listing requirement to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the " Bid Price Rule "), as the Company's closing bid price was less than $1.00 per share for the 30 consecutive business days prior the date of the Nasdaq notice. On November 6, 2025, the Company received a letter from Nasdaq (the " Letter ") stating that although the Company had not regained compliance with the Bid Price Rule, Nasdaq determined that the Company is eligible for an additional 180-day period, or until May 4, 2026, to regain compliance with the Bid Price Rule. In the Letter, Nasdaq stated that its determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the minimum bid price requirement, and (ii) the Company's written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this second 180-day compliance period, the closing bid price of the Company's common stock is at least $1 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance to the Company, and this matter will be closed. If compliance cannot be demonstrated by May 4, 2026, Nasdaq will provide written notification that the common stock will be delisted. At that time, the Company would have an opportunity to appeal the delisting determination to a Nasdaq Listing Qualifications Panel. The Company intends to moni
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-KEY INTERNATIONAL, INC. Date: November 7, 2025 By: /s/ Cecilia C. Welch Cecilia C. Welch Chief Financial Officer